Lipella Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)5holders −2
1new positions
3sold out
$0.47avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Lipella Pharmaceuticals Inc. in their 13F filings, down 2 from Q2 2024. 1 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($16K), Geode Capital Management, LLC ($12K) and HRT Financial LP ($8K).
- Company
- Lipella Pharmaceuticals Inc.
- CUSIP
- 53630L100
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8K |
| Exits | 3 | $253K |
All 13F filers, Q2 2024 → Q3 2024: 17,620 shares bought and 563,116 shares sold, net −545,496 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Vanguard Group Inc. | 0.00% | No change | 34,520 | $16K |
| Geode Capital Management, LLC | 0.00% | Reduce -4.2% | 24,915 | $12K |
| HRT Financial LP | 0.00% | New | 17,619 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.3% | 7,694 | $4K |
| Bank of America Corp. | 0.00% | Add +2.2% | 47 | $22 |
"% of holder's portfolio" is LIPELLA PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Lipella Pharmaceuticals Inc. the manager owns.